New combo therapy shows promise for Tough-to-Treat lymphoma
NCT ID NCT05364424
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 34 times
Summary
This early-phase study tested a new drug, glofitamab, combined with standard chemotherapy (R-ICE) in 43 people with diffuse large B-cell lymphoma that returned or didn't respond to first treatment. Participants were eligible for a stem cell transplant or CAR-T therapy. The goal was to see if the combination could shrink tumors and how safe it was.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chao Family Comprehensive Cancer Center UCI
Orange, California, 92868, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Cancer Institute at Memorial West
Pembroke Pines, Florida, 33028, United States
-
New York University Langone Medical Center
New York, New York, 10016, United States
-
The University of Chicago
Chicago, Illinois, 60637, United States
-
Tulane Medical Center
New Orleans, Louisiana, 70112, United States
-
UMASS Memorial Medical Center
Worcester, Massachusetts, 01655, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.